Filtered By:
Specialty: International Medicine & Public Health
Condition: Heart Failure
Countries: Australia Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
EE352 Projecting the Incidence and Costs of Major Cardiorenal Complications of Type 2 Diabetes with Widespread GLP-1 RA and SGLT2I Use
Whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose co-transporter 2 inhibitors (SGLT2is) are cost-effective when considering solely their cardiorenal benefits is unknown. We projected the incidence and costs of hospitalisation for myocardial infarction (MI), stroke, and heart failure (HF), and end-stage kidney disease (ESKD) among people with type 2 diabetes under scenarios of widespread use of these drugs, from an Australian healthcare perspective.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: J Morton, C Marquina, JE Shaw, D Liew, Z Ademi, D Magliano Source Type: research
